Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | LPL | P06858 | 2/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 3/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 3/20 | 0.35 |
| ▸ | PPARA | Q07869 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29792085 | 1.00 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4DLIPE | |
| SCHEMBL15670098 | 0.87 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DLIPE | |
| SCHEMBL1128760 | 0.84 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4DLIPE | |
| SCHEMBL13860167 | 0.82 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4DLIPE | |
| SCHEMBL30143835 | 0.82 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4DLIPE | |
| SCHEMBL16470841 | 0.82 | RAB9A (0.42) | LIPEPPARG | |
| SCHEMBL19230506 | 0.81 | SNCA (0.41) | PDE4APDE4BPDE4CPDE4DLPL | |
| SCHEMBL1129675 | 0.81 | LTA4H (0.43) | PDE4APDE4BPDE4CPDE4DLIPE | |
| SCHEMBL1129617 | 0.80 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DLIPE | |
| SCHEMBL1128925 | 0.79 | LIPE (0.43) | PDE4APDE4BPDE4CPDE4DLIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364079-A1 | COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230257383-A1 | COMPOUND SERVING AS BTK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257383-A1 | COMPOUND SERVING AS BTK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| EP-4186906-A1 | COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Chengdu Hyperway Pharmaceuticals Co., Ltd. (CN) | 2023-05-31 | — | — | EP | disclosed |
| CN-112424203-B | Bruton's tyrosine kinase inhibitors | 正大天晴药业集团股份有限公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-112424203-A | Bruton's tyrosine kinase inhibitors | 正大天晴药业集团股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| WO-2020015735-A1 | BRUTON TYROSINE KINASE INHIBITORS | 正大天晴药业集团股份有限公司 | 2020-01-23 | — | — | WO | disclosed |
| WO-2020015735-A1 | BRUTON TYROSINE KINASE INHIBITORS | 正大天晴药业集团股份有限公司 | 2020-01-23 | — | — | WO | disclosed |
| US-8481733-B2 | Substituted imidazopyr- and imidazotri-azines | OSI Pharmaceuticals, LLC (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2283020-B1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARM INC (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | ABL1, TPMT, CYP2C19 | PDE4A 1037/4885PDE4B 1682/4885PDE4C 1999/4885 |
| US-20230257383-A1 | COMPOUND SERVING AS BTK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | BTK, WEE1, WEE2 | PDE4A 3261/4885PDE4B 2553/4885PDE4C 2936/4885 |
| US-20230364079-A1 | COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | BTK, WEE2, WEE1 | PDE4A 4456/4885PDE4B 4043/4885PDE4C 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.